EXPERIENCEYou Can Trust
Mario prides himself on quality service.
SPIRIVA® in COPD improves his quality of life
SPIRIVA® Respimat® significantly improved quality of life (QoL)*
The proportion of responders (those whose total SGRQ scores fell by ≥4 units from baseline) was significantly higher in the SPIRIVA® Respimat® group than the placebo group (-4.7 vs -1.8 units, respectively)
*The St. George’s Respiratory Questionnaire (SGRQ) is a recognised indicator of health-related quality of life, measuring impairment on a scale of 0 to 100. Minimal clinically important difference in SGRQ is defined as 4 units.
Reference
1. Bateman ED, Tashkin D, Siafakas N, et al. A one-year trial of tiotropium Respimat® plus usual therapy in COPD patients. Respir Med. 2010;104(10):1460-1472.
From a 1-year, randomised, double-blind study of COPD patients receiving SPIRIVA® Respimat® 2.5 μg administered once daily in two puffs (5 μg) or placebo. Coprimary endpoints were trough FEV1 and time to first exacerbation during the study period. Patients were allowed to take all other types of COPD treatments except for inhaled anticholinergics.